Introduction: To develop and evaluate a technique of 3.0 Tesla magnetic resonance (MR) guided laser ablation based on 3-dimentional mapping biopsy (3DMB) for low risk prostate cancer. Materials and Methods: The study was approved by the institutional review board and was the Health Insurance Portability and Accountability Act compliant. The prospective study was performed on seven 3DMB proven low risk prostate cancer patients. In the first phase of the procedure the patient's prostate was aligned to a position concordant with prior 3DMB using the transperineal grid and fiduciary golden marker coordinates. In the second phase ablation was performed using MR thermometry to determine the ablation endpoint and lesion coverage. Immediately after treatment dynamic contrast-enhanced MR imaging was done. Prostate-specific antigen testing was performed 3 and 12 months after the treatment and compared by ANOVA test. A follow up biopsy was done one year following ablation. Results: The entire procedure took less than 2 hours and all patients tolerated the procedure well. There was a significant difference in prostate-specific antigen value before and 3 months after the treatment (p = 0.005). Four out of 6 patients had positive follow up biopsy for cancer. Conclusion: This study verifies the feasibility and safety of treating low risk prostate cancer with laser therapy guided by 3.0T MR imaging based on 3DMB.

Keywords:
Prostate cancer, Focal therapy, MRI, Ultrasound, Prostate biopsy
1.
Kim J, Ebertowski J, Janiga M, Arzola J, Gillespie G, Fountain M, Soderdahl D, Can-by-Hagino E, Elsamanoudi S, Gurski J, Davis JW, Parker PA, Boyd DD: Many young men with prostate-specific antigen (PSA) screen-detected prostate cancers may be candidates for active surveillance. BJU Int 2013;111:934-940.
2.
Sullivan KF, Crawford ED: Targeted focal therapy for prostate cancer: a review of the literature. Ther Adv Urol 2009;1:149-159.
3.
Barqawi AB, Stoimenova D, Krughoff K, Eid K, O'Donnell C, Phillips JM, Crawford ED: Targeted focal therapy in the management of organ confined prostate cancer. J Urol 2014;192:749-753.
4.
Barqawi AB, Krughoff KJ, Eid K: Current challenges in prostate cancer management and the rationale behind targeted focal therapy. Adv Urol 2012;2012:862639.
5.
Barqawi AB, Rove KO, Gholizadeh S, O'Donnell CI, Koul H, Crawford ED: The role of 3-dimensional mapping biopsy in decision making for treatment of apparent early stage prostate cancer. J Urol 2011;186:80-85.
6.
Crawford ED, Rove KO, Barqawi AB, Maroni PD, Werahera PN, Baer CA, Koul HK, Rove CA, Lucia MS, La Rosa FG: Clinical-pathologic correlation between transperineal mapping biopsies of the prostate and three-dimensional reconstruction of prostatectomy specimens. Prostate 2013;73:778-787.
7.
Ahmed HU, Hu Y, Carter T, Arumainayagam N, Lecornet E, Freeman A, Hawkes D, Barratt DC, Emberton M: Characterizing clinically significant prostate cancer using template prostate mapping biopsy. J Urol 2011;186:458-464.
8.
Taira AV, Merrick GS, Galbreath RW, An dreini H, Taubenslag W, Curtis R, Butler WM, Adamovich E, Wallner KE: Performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting. Prostate Cancer Prostatic Dis 2009;13:71-77.
9.
Barzell WE, Melamed MR: Appropriate patient selection in the focal treatment of prostate cancer: the role of transperineal 3-dimensional pathologic mapping of the prostate—a 4-year experience. Urology 2007;70(6 suppl):27-35.
10.
Patel V, Merrick GS, Allen ZA, Andreini H, Taubenslag W, Singh S, Butler WM, Adamovich E, Bittner N: The incidence of transition zone prostate cancer diagnosed by transperineal template-guided mapping biopsy: implications for treatment planning. Urology 2011;77:1148-1152.
11.
Stafford RJ, Shetty A, Elliott AM, Klumpp SA, McNichols RJ, Gowda A, Hazle JD, Ward JF: Magnetic resonance guided, focal laser induced interstitial thermal therapy in a canine prostate model. J Urol 2010;184:1514-1520.
12.
Woodrum DA, Gorny KR, Mynderse LA, Amrami KK, Felmlee JP, Bjarnason H, Garcia-Medina OI, McNichols RJ, Atwell TD, Callstrom MR: Feasibility of 3.0T magnetic resonance imaging-guided laser ablation of a cadaveric prostate. Urology 2010;75:1514. e1-6.
13.
D'Amico AV, Whittington R, Malkowicz SB, Weinstein M, Tomaszewski JE, Schultz D, Rhude M, Rocha S, Wein A, Richie JP: Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era. J Urol 2001;166:2185-2188.
14.
Barqawi AB, Rove KO, Gholizadeh S, et al: The role of 3-dimensional mapping biopsy in decision making for treatment of apparent early stage prostate cancer. J Urol 2011;186:80-85.
15.
Chu KF, Dupuy DE: Thermal ablation of tumours: biological mecahnisms and advances in therapy. Nat Rev Cancer 2014;14:199-208.
16.
Oto A, Sethi I, Karczmar G, McNichols R, Ivancevic MK, Stadler WM, Watson S, Eggener S: MR imaging-guided focal laser ablation for prostate cancer: phase I trial. Radiology 2013;267:932-940.
17.
Raz O, Haider MA, Davidson SR, Lindner U, Hlasny E, Weersink R, Gertner MR, Kucharczyk W, McCluskey SA, Trachtenberg J: Real-time magnetic resonance imaging-guided focal laser therapy in patients with low-risk prostate cancer. Eur Urol 2010;58:173-177.
18.
Woodrum DA, Mynderse LA, Gorny KR, Amrami KK, McNichols RJ, Callstrom MR: 3.0T MR-guided laser ablation of a prostate cancer recurrence in the postsurgical prostate bed. J Vasc Interv Radiol 2011;22:929-934.
19.
Alonzi R, Padhani AR, Allen C: Dynamic contrast enhanced MRI in prostate cancer. Eur J Radiology 2007;63:335-350.
20.
Ploussard G, Epstein JI, Montironi R, Carroll PR, Wirth M, Grimm MO, Bjartell AS, Montorsi F, Freedland SJ, Erbersdobler A, van der Kwast TH: The contemporary concept of significant versus insignificant prostate cancer. Eur Urol 2011;60:291-303.
21.
Donaldson IA, Alonzi R, Barratt D, Barret E, Berge V, Bott S, Bottomley D, Eggener S, Ehdaie B, Emberton M, Hindley R, Leslie T, Miners A, McCartan N, Moore CM, Pinto P, Polascik TJ, Simmons L, van der Meulen J, Villers A, Willis S, Ahmed HU: Focal therapy: patients, interventions, and outcomes-a report from a consensus meeting. Eur Urol 2015;67:771-777.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.